dostarlimab,cobolimab,nivolumab
bms,gsk
['nivo', 'dostarlimab', 'nivolumab', 'cobolimab']
proud of dr falchook!! phase 1 trial of tim-3 inhibitor cobolimab monotherapy and in combination with pd-1 inhibitors nivolumab or dostarlimab (amber).#asco2022
Medical oncologist whose focus is drug development for lung cancer patients being treated in the community.